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Malignant gliomas are the most prevalent
type of primary central nervous system
(CNS) tumor in adults. Despite progress
in brain tumor therapy, the prognosis
for malignant glioma patients remains
dismal. Standard treatment with temo-
zolomide and radiotherapy for patients
with newly diagnosed glioblastoma has
increased the median overall survival (OS)
by 15–20 months (1), but tumor recur-
rence is inevitable. Salvage treatments
upon recurrence are palliative at best and
rarely provide significant survival bene-
fit. Among the new treatments currently
being investigated for malignant glioma,
immunotherapy is theoretically attractive,
because it offers the potential for high
tumor-specific cytotoxicity (2). Although
recent clinical trials of immunotherapy
protocols for malignant gliomas focused on
initiating and amplifying a host response
with some clinical success, most of them
failed to induce objective tumor shrink-
age in patients (2). Antitumor activities
of tumor cytotoxic T cells (CTL) and
antibodies induced by these therapies are
insufficient to overcome tumor growth
because tumors have immune evasion
mechanisms instigated by myeloid derived
suppressor cells (MDSCs) and regulatory T
cells (Treg) (3). In this paper, we will review
past experiences and discuss the promising
future of immunotherapeutic approach for
glioma treatment.
WHAT HAVE WE LEARNED FROM
PREVIOUS CLINICAL TRIALS?
Preliminary results from recent
immunotherapeutic clinical trials (2, 4–
6) with dendritic cells or peptide vaccines
for malignant glioma patients are encour-
aging. However, these trials have some
limitations, and we will have to await the
results of several phase III trials to make
definitive conclusions. There are several
concerns from past experiences.
1. The immune responses such as CTL and
antibody production were not sufficient
to overcome glioma progression, and
were not correlated to clinical outcomes.
2. New issues have emerged regarding the
evaluation of disease response, and with
the identification of patterns such as
pseudoprogression (7) that is frequently
indistinguishable from disease progres-
sion. Additionally, there are delayed
radiation responses after radiotherapy.
In short, there are pitfalls in distinguish-
ing the response of radiotherapy to that
of immunotherapy.
3. There are prognostic variations and
long term survivors among glioblas-
toma patients (8). We therefore have to
develop molecular markers to predict
the prognosis of the patient more pre-
cisely to conduct clinical trials with less
bias.
4. We have to develop biomarkers that
predict patients’ responses to indi-
vidualized immunotherapy. To do so,
we have to conduct clinical trials that
exclude patients with pseudoprogres-
sion, a delayed radiation response and a
biologically good prognostic group.
5. Most immunotherapy clinical trials
state that the therapy is safe. This is a
concern because the adverse events of
immunotherapy are usually interpreted
as those of the clinical course of glioma.
We have to continue to carefully moni-
tor patients, because acute disseminated
encephalomyelitis and neuropathic syn-
drome following vaccination against
human papillomavirus for cervical can-
cer are now serious problems (9).
6. In recent years, there has been a signif-
icant increase in OS and progression
free survival (PFS) owing to improve-
ments in standard of care (10). In
phase II clinical trials, survival data are
usually compared to that of a decade
ago, so emerging therapeutics are easily
misconstrued as effective therapies.
7. In Japan, bevacizumab was approved
for glioblastoma in June 2013. There-
fore, we should reconsider whether
an immunotherapeutic approach for
glioma could be a new standard of care.
8. In Japan, medical oncologists are
expected to participate in the devel-
opment of global immunotherapeutic
protocols for glioblastoma.
PROGNOSTIC MARKERS FOR
GLIOBLASTOMA
The World Health Organization (WHO)
currently has the most widely used sys-
tem for prognostic markers; a high WHO
grade correlates with clinical progression
and decreased survival rate (11). How-
ever, individual fates vary within diag-
nostic categories. There are several prog-
nostic factors that are associated with
longer survival of glioblastoma patients,
including age, performance status (PS),
MGMT status, and IDH1 mutation. The
inadequacy of histopathological grading is
shown, in part, by the inability to recog-
nize patients prospectively. We and other
researchers have developed a predictive
method for patient outcome that enables
clinicians to make optimal clinical deci-
sions using microarray technology (8, 12–
14). Our work described an expression
profiling study of glioblastoma patients
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FIGURE 1 | Survival analyses using the selected 25 gene
classifiers show prognostic value for glioblastoma. Kaplan–Meier
curves that compare groups classified by the Z1 PPS with the 25 gene
model in the test set (A) and validation set (B). Permission for reuse
was obtained from John Wiley & Sons Ltd. and ©2013 Japanese
Cancer Association.
for the identification of genes that predict
OS using random survival forests models
(8). The gene expression predictor, which
we named the Prognosis Prediction Score
(PPS), was computed from a linear com-
bination of 25 selected genes and was
calculated for each tumor as follows:
Z1 = 0.27× GPNMB + 0.09× EFNB2
− 0.22× ASF1A + 0.02
× LOC283027+ 0.15× AMIGO2
+ 0.22× IL13RA2+ 0.25× ITGA7
+ 0.15× LDHA − 0.01× C11orf 71
+ 0.15× AFTPH + 0.15
× TBC1D19− 0.21×MED29
+ 0.02× ACN 9+ 0.29
× SLC25A19+ 0.16× RPL12
− 0.09× ALS2CR4− 0.14
× C10orf 88− 0.11× ARHGAP39
+ 0.18× LMAN 2L + 0.29× CASP8
− 0.28× ST 6GAL2+ 0.33× LOXL3
+ 0.08× ANGPTL1+ 0.22×MRRF
− 0.33× ARHGAP32.
As expected, the predictor performed well
in terms of patient prognosis: the improved
prognosis group (Z1≤−1.17) had a
median survival time of 721 days, while the
poor prognosis group (Z1 >−1.17) had a
significantly lower median survival time of
335 days (P< 0.0001; Figure 1A). For more
practical purposes, the PPS could also be
computed from a linear combination of
three genes and was calculated for each
tumor as follows:
Z2 = − 0.63× ASF1A + 0.62× ITGA7
+ 0.47× AFTPH .
As expected, the predictor per-
formed well in terms of patient prog-
nosis: the improved prognosis group
(Z2≤−0.76) and the poor prognosis
group (Z2 >−0.76) had identical median
survival times and significance scores as Z1.
The Z PPS results were compared with tra-
ditional individual indicators. Z1, Z2, age,
PS, and subtype were significantly associ-
ated with OS in univariate analyses. Z1 was
significantly associated with OS by mul-
tivariate analyses. The PPS was the most
significant feature of these clinical parame-
ters. The PPS formula was validated in the
validation set (n= 488), which was derived
from glioblastoma patients in four exter-
nal data sets (12–15). As expected, the OS
was significantly higher in the improved
prognosis group (Z1≤−1.17) than in
the poor prognosis group (Z1 >−1.17)
(P = 0.0016; Figure 1B). Two-year survival
rates were 36.3 and 30.8% in the improved
prognosis group, and 4.7 and 11.8% in
the poor prognosis group, using the test
and validation data sets, respectively. Even
among glioblastomas in both test (n= 32)
and validation sets (n= 488), the OS
ranged between 0 and 3,880 days. Fifty-
two patients (10%) survived for longer
than 1,000 days. Class prediction models
based on defined molecular profiles allow
the classification of malignant gliomas
in a manner that will better correlate
with clinical outcomes than with standard
pathology. Glioblastomas have a wide-
ranging survival time, which requires a
more precise prognostic scoring system
to study novel therapeutic approaches.
Therefore, the identification of molecular
subclasses could greatly facilitate our ability
to develop effective treatment protocols.
FUTURE PERSPECTIVES
The genetic landscape of gliomas has
been revealed by the advancements of
genome sequencing technology (15, 16).
Researchers are now trying to develop
novel therapeutic strategies based on
these exciting discoveries. New thera-
peutic strategies, such as targeted thera-
pies and anti-angiogenic treatments that
appear promising with regard to improv-
ing the results have been reported
(17). Immunotherapies have also shown
promise for treating advanced solid
tumors. In particular, monoclonal anti-
bodies that block inhibitory immune
checkpoint molecules and enhance the
immune response to tumors such as
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cytotoxic T-lymphocyte-associated antigen
4 (CTLA4) and programed cell death pro-
tein 1 (PD-1) (18, 19). Another fore-
front of immunotherapy research is genet-
ically engineering T cells to target tumor
cells (20). Future efforts will need to
focus on development of novel therapies
that appear active as monotherapies or in
combinatorial regimens that modulate the
host immune system. Although it is still
unknown whether these novel discoveries
will be suited for use in the CNS microen-
vironment, we are awaiting the next gener-
ation of progress for glioma immunother-
apy based on the fundamental pathophysi-
ology of this challenging disease.
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